BioCentury | Aug 29, 2019
Distillery Techniques

The E3 ligase CHIP as an Alzheimer's disease biomarker

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Tissue markers; gene profiling Hippocampal expression levels of CHIP, an E3 ubiquition ligase, could serve as a biomarker of AD severity. High levels of a tau (microtubule-associated protein tau; MAPT; FTDP-17)...
BioCentury | Aug 28, 2018
Preclinical News

Stealth start-up Quench among teams tying protein to inflammatory cell death

Atlas Venture-backed start-up Quench Bio has partnered with a Max Planck Institute for Infection Biology team to target an inflammatory cell death pathway implicated in inflammatory and autoimmune diseases. The company, which is funded by...
BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a small...
BioCentury | Dec 10, 2016
Product Development

Rules of the road

Investigators and companies have long been devising strategies to mitigate or preempt toxicities from CAR T cell therapies without compromising efficacy. Now, data presented at the American Society of Hematology meeting suggest strategies to prevent...
BioCentury | Jun 13, 2016
Company News

Bellicum, Leiden University Medical Center deal

Bellicum and the center partnered to discover and validate high-affinity T cell receptor (TCR) candidates to treat cancer. The biotech, which will provide its CaspaCIDe switch technology, will have exclusive, worldwide rights to compounds discovered...
BioCentury | May 5, 2016
Targets & Mechanisms

Better call Delilah

Long non-coding RNAs (lncRNAs), once confined to the pile of non-functional genomic "junk," are now recognized to play key roles in gene regulation, and are increasingly being explored in various cancers. A Belgian group has...
BioCentury | Feb 4, 2016
Tools & Techniques

Calibrating CARs

Instead of focusing on how to turn chimeric antigen receptor (CAR) T cells off when things go wrong, a group at the California Institute for Biomedical Research (Calibr) has engineered a universal CAR T cell...
BioCentury | Jan 11, 2016
Clinical News

Emricasan: Phase II data

A double-blind, U.S. Phase II trial in 86 patients with liver cirrhosis showed that twice-daily 25 mg oral emricasan significantly reduced cleaved CK18 levels from baseline to 3 months vs. placebo (reduction of 4.6% vs....
BioCentury | Nov 2, 2015
Emerging Company Profile

Targeted disruption

PEP-Therapy S.A.S. is developing fusion peptides for cancer that block specific intracellular protein-protein interactions, which could be safer than broad inhibitors of the same proteins. The company's fusion peptides comprise an optimized cell-penetrating peptide that...
BioCentury | Jul 27, 2015
Company News

CleveXel Pharma, PEP-Therapy deal

The companies partnered to co-develop a peptide from PEP-Therapy to treat cancer through clinical proof of concept. The cell-penetrating peptide targets the interaction between caspase-9 ( CASP9 ; MCH6 ) and protein phosphatase 2 ( PPP2CA ; PP2A...
Items per page:
1 - 10 of 62